HB 56
|
Allows pharmaceutical companies to rebate portions of copayments to multiple sclerosis patients without violating anti-kickback and anti-rebate laws
    
Handler: Dolan
|
|
|
Current Bill Summary
|
- Prepared by Senate Research -
|
|
HCS/HB 56 - This act provides that the anti-kickback, anti-rebating and other prohibited financial incentive provisions of Section 191.905 shall not apply to pharmaceutical programs that rebate a portion of health insurance copayments and coinsurance to multiple sclerosis patients or others suffering from chronic conditions who have been prescribed medicines for which there are no generic equivalents.STEPHEN WITTE
|
|
|
Go to Main Bill Page
|
Return to Summary List
|
Return to Senate Home Page
|